In 1989, a research group from DKFZ found that monoclonal antibodies targeting APO-1 (also known as CD95 or FasR) on human lymphoma cells trigger apoptosis of lymphoma cells in vivo and induce regression of lymphoma in a mouse model1. Here, FAS is linked to lymphoma.